Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE:JNJ) and Roche Holding AG (OTC:RHHBY) each reported fairly robust results.
Four healthcare stocks, including biotechs and medical device makers, debuted on Wall Street this week, raising $413.3 million in gross proceeds.
Ocugen, Inc. (NASDAQ:OCGN) was among the biggest gainers of the week, having advanced over 110% on the back of a positive clinical readout for a partnered COVID-19 vaccine candidate.
Here are the key catalysts for the unfolding week:
International Organization for Medical Physics', or IOMP, International Medical Physics Week: April 26-30UBS Asia Virtual Healthcare Summit: April 27-29B. Riley's Neuroscience Investor Conference: April: April 28—292021 Society of Biological Psychiatry, or SOBP, annual meeting: April 29-May 1Association for Research In Vision and Ophthalmology, or ARVO, 2021 Virtual Meeting: May 1-7
The Food and Drug Administration is scheduled to announce its verdict on Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) new drug application for Epsolay in the treatment of inflammatory lesions of rosacea. The PDUFA date, or the deadline for announcing the decision, is Monday.
The FDA will also rule on Protalix BioTherapeutics, Inc.'s (NYSE:PLX) biologic license application for pegunigalsidase alfa in Fabry disease. The PDUFA date is set for Tuesday.
By Thursday, the regulatory agency is mandated to make a decision on Ardelyx, Inc.'s (NASDAQ:ARDX) new drug application for tenapanor in hyperphosphatemia.
Related Link: BofA Says GlaxoSmithKline's Decision To Halt Feladilimab Studies Is Disappointing
Nanobiotix S.A. (NASDAQ:NBTX) is scheduled to present at the IOMP's physics week, further data from the Phase 1 expansion data for NBTXR3 in head and neck cancer.
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) will host a webinar at 8 a.m., Tuesday, to provide a corporate update on clinical programs for its CY6463 in Alzheimer's disease with vascular pathology and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes.
Trillium Therapeutics Inc. (NASDAQ:TRIL) will host its virtual R&D Day for analysts and investors at 10:00 am – 1:00 pm on Wednesday, wherein it will provide a clinical update for TTI-622 in refractory lymphoma or multiple myeloma, and TTI-621 in diffuse Large B-cell Lymphoma (DLBCL), cutaneous T-cell lymphoma.
Aptinyx Inc. (NASDAQ:APTX) is due to present at the SOBP annual meeting, data from the Phase 2a exploratory study of NYX-783 in posttraumatic stress disorder.
Annovis Bio, Inc. (NYSE:ANVS) is scheduled to release in April interim data for ANVS401 in Alzheimer's and Parkinson's diseases.
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is set to present at the ARVO annual meeting updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) (before the market open)Masimo Corporation (NASDAQ:MASI) (after the close)
Eli Lilly and Company (NYSE:LLY) (before the market open)AtriCure, Inc. (NASDAQ:ATRC) (after the close)Amgen Inc. (NASDAQ:AMGN) (after the close)Illumina, Inc. (NASDAQ:ILMN) (after the close)
Boston Scientific Corporation (NYSE:BSX) (before the market open)Surmodics, Inc. (NASDAQ:SRDX) (before the market open)Integra LifeSciences Holdings Corporation (NASDAQ:IART) (before the market open)Alkermes plc (NASDAQ:ALKS) (before the market open)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) (after the close)Alimera Sciences, Inc. (NASDAQ:ALIM) (after the close)OPKO Health, Inc. (NASDAQ:OPK) (after the close)Hologic, Inc. (NASDAQ:HOLX) (after the close)Viking Therapeutics, Inc. (NASDAQ:VKTX) (after the close)
Syneos Health, Inc. (NASDAQ:SYNH) (before the market open)NovoCure Limited (NASDAQ:NVCR) (before the market open)West Pharmaceutical Services, Inc. (NYSE:WST) (before the market open)Merck & Co., Inc. (NYSE:MRK) (before the market open)Evelo Biosciences, Inc. (NASDAQ:EVLO) (before the market open)Baxter International Inc. (NYSE:BAX) (before the market open)Bristol-Myers Squibb Company (NYSE:BMY) (before the market open)Blueprint Medicines Corporation (NASDAQ:BPMC) (before the market open)Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (before the market open)Laboratory Corporation of America Holdings (NYSE:LH) (before the market open)Abiomed, Inc. (NASDAQ:ABMD) (before the market open)Amarin Corporation plc (NASDAQ:AMRN) (before the market open)Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) (before the market open)ResMed Inc. (NYSE:RMD) (after the close) (after the close)MiMedx Group, Inc. (NASDAQ:MDXG) (after the close)BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) (after the close)Pacific Biosciences of California, Inc. (NASDAQ:PACB) (after the close)Bio-Rad Laboratories, Inc. (NYSE:BIO) (after the close)Emergent BioSolutions Inc. (NYSE:EBS) (after the close)ChemoCentryx, Inc. (NASDAQ:CCXI) (after the close)DexCom, Inc. (NASDAQ:DXCM) (after the close)Gilead Sciences, Inc. (NASDAQ:GILD) (after the close)Merit Medical Systems, Inc. (NASDAQ:MMSI) (after the close)LeMaitre Vascular, Inc. (NASDAQ:LMAT) (after the close)MacroGenics, Inc. (NASDAQ:MGNX) (after the close)Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (after the close)Seagen Inc. (NASDAQ:SGEN) (after the close)
AbbVie Inc. (NYSE:ABBV) (before the market open)
IPOs Quiet Period Expiries
Achilles Therapeutics plc (NASDAQ:ACHL)
Related Link: Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline
Kopin® Corporation (NASDAQ: KOPN), a leading developer and provider of transmissive and reflective active matrix liquid crystal and organic light emitting diode (OLED) microdisplays and display subassemblies for military, enterprise, industrial, consumer and medical products, today announced that its BDM® WVGA LCD module and A912 Driver IC have been chosen by Medisim Ltd. for its BinoVision™ goggles.
Medisim Ltd., based in Israel, developed the novel and patented product - BinoVision™, aiming to treat Amblyopia (Lazy Eye). The binocular head-mounted video goggle connects to most streaming video sources (computer, TV, game console, etc.) and uses the content (movies, cartoons, games, music videos, TV shows) to enable brain stimulation. BinoVision™ is content agnostic, so compliance is high. A published clinical study results of the technology showed that dichoptic stimulation of the visual system can significantly improve visual function in just 4 weeks. A feasibility study at Indiana University suggested BinoVision™ goggles, with some modifications, may also be used in the future for glaucoma. In a published study, the technology demonstrated increasing ocular blood flow and retinal perfusion both in glaucoma patients and healthy subjects.
"Kopin’s knowledge of microdisplays and optical modules was very apparent to us during our process of selecting a near-to-eye LCD,” said Ilan Vadai, CEO, Medisim Ltd. "Kopin’s WVGA module and A912 ASIC were key components necessary to bring BinoVision™ to fruition. Kopin’s displays provide a high level of brightness - a key requirement for our application. In addition, with the displays and optics precisely aligned and securely packaged in a binocular module, the ease of integration was unmatched.”
"We are delighted that Medisim Ltd. has selected our products for its BinoVision™ goggles, and want to congratulate them on their success,” said Greg Truman, Head of Industrial and Enterprise Displays, Kopin. "We are excited by the increased interest in our microdisplays for medical products and believe a variety of applications such as surgical, procedural, ophthalmic and others can benefit from the integration of our near-to-eye microdisplays.”
Headquartered in Westborough, Massachusetts, Kopin and its subsidiaries offer a variety of industry leading microdisplay product lines, including LCD, OLED and FLCoS displays. Kopin’s BDM-WVGA (LCD) delivers a large (42?-diagonal size viewed at 6.5-foot distance), crisp image. The lightweight (16g), compact binocular display module integrates two 16: 9 widescreen CyberDisplay® WVGA LVD (854x480 resolution) color filter displays, LED backlights and a pair of pre-aligned high-quality lenses (30 degree field of view) into plastic housing. The BDM-WVGA is driven by Kopin’s A912 controller IC. The BDM-WVGA is a drop in solution, meant to speed up eyewear development and enable OEMs to design-in products quickly and efficiently.
Kopin, CyberDisplay and BDM are registered trademarks of Kopin Corporation.
Kopin Corporation is a leading developer and provider of innovative display and optical technologies sold as critical components and subassemblies for military, industrial and consumer products. Kopin's technology portfolio includes ultra-small Active Matrix Liquid Crystal displays (AMLCD), Liquid Crystal on Silicon (LCOS) displays and Organic Light Emitting Diode (OLED) displays, a variety of optics, and low-power ASICs. For more information, please visit Kopin's website at www.kopin.com.
About Medisim Ltd.
Medisim Ltd. is a developer and manufacturer of innovative diagnostic medical devices. Founded in 1995, Medisim's headquarters and manufacturing plant are based in Israel, with subsidiaries in the USA and Hong Kong. As an R&D centric company, continually allocating substantial resources into developing innovative, cost-efficient and highly scalable medical solutions, Medisim is proud of its innovative spirit and contribution to enhancing peoples’ health. For more information, please visit Medisim website at: https://www.medisim.co.il
Statements in this press release may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject to the safe harbor created by such sections. Words such as "expects," "believes," "can," "will," "estimates," and variations of such words and similar expressions, and the negatives thereof, are intended to identify such forward-looking statements. We caution readers not to place undue reliance on any such "forward-looking statements," which speak only as of the date made, and advise readers that these forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties, estimates, and assumptions by us that are difficult to predict. These forward-looking statements may include statements with respect to: Our belief that a variety of applications such as surgical, procedural, ophthalmic and others can benefit from the integration of our near-to-eye microdisplays. Various factors, some of which are beyond our control, could cause actual results to differ materially from those expressed in, or implied by, such forward-looking statements. All such forward-looking statements, whether written or oral, and whether made by us or on our behalf, are expressly qualified by these cautionary statements and any other cautionary statements that may accompany the forward-looking statements. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as may otherwise be required by the federal securities laws. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management's expectations are described in Part I, Item 1A. Risk Factors; Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations; and other parts of our Annual Report on Form 10-K for the fiscal year ended December 28, 2019, or as updated from time to time in the Company's Securities and Exchange Commission filings.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005049/en/
Barry Silbert, a power player in the digital-asset sector, earlier this week tweeted that he...